产品
编 号：F754772
分子式：C15H30ClN3O2
分子量：319.87
分子式：C15H30ClN3O2
分子量：319.87
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 2703451-51-6
产品详情
生物活性：
ENMD-1068 hydrochloride is a selective protease-activated receptor 2 (PAR2) antagonist. ENMD-1068 hydrochloride reduces hepatic stellate cell activation and collagen expression by inhibiting TGF-β1/Smad signaling. ENMD-1068 hydrochloride also inhibits the proliferation of endometrial cells and induces apoptosis of epithelial cells in the lesion. ENMD-1068 hydrochloride can be used in the study of endometriosis and liver fibrosis.
体内研究：
ENMD-1068（25、50 mg/kg；腹腔注射；每周两次，持续 4 周）抑制小鼠肝纤维化。ENMD-1068（25、50 mg/kg；腹腔注射；每日一次，持续 5 天）可抑制子宫内膜异位症生长并以剂量依赖性方式抑制 IL-6 和 MCP-1 水平。ENMD-1068（25、50 mg/kg；腹腔注射；每天一次，持续 5 天）会导致小鼠上皮细胞增殖减少，细胞凋亡指数增加。Animal Model:ICR mice (8-week-old; CCl4-induced liver fibrosis model).
Dosage:25, 50 mg/kg
Administration:Intraperitoneal injection; twice per week for 4 weeks
Result:Markedly attenuated collagen deposition.
Animal Model:Mice with surgically induced endometriosis.
Dosage:25, 50 mg/kg
Administration:Intraperitoneal injection; single daily for 5 days
Result:Reduced the volume of observed lesions in a dose-dependent manner.Inhibited the expression of IL-6 and MCP-1.Decreased the proliferation rate of endometriotic cells and increased the percentage of apoptotic epithelial cells in the lesions.
体外研究：
ENMD-1068（10 mM；24 小时）阻断原代小鼠 HSC 中的 TGF-β1/Smad 信号传导（TGF-β1/Smad 信号通路在 HSC 激活和胶原蛋白生成中发挥着至关重要的作用）。ENMD-1068 (10 mM) 抑制 HSC 中胰蛋白酶或 SLIGRL-NH2 刺激的钙释放。
ENMD-1068 hydrochloride is a selective protease-activated receptor 2 (PAR2) antagonist. ENMD-1068 hydrochloride reduces hepatic stellate cell activation and collagen expression by inhibiting TGF-β1/Smad signaling. ENMD-1068 hydrochloride also inhibits the proliferation of endometrial cells and induces apoptosis of epithelial cells in the lesion. ENMD-1068 hydrochloride can be used in the study of endometriosis and liver fibrosis.
体内研究：
ENMD-1068（25、50 mg/kg；腹腔注射；每周两次，持续 4 周）抑制小鼠肝纤维化。ENMD-1068（25、50 mg/kg；腹腔注射；每日一次，持续 5 天）可抑制子宫内膜异位症生长并以剂量依赖性方式抑制 IL-6 和 MCP-1 水平。ENMD-1068（25、50 mg/kg；腹腔注射；每天一次，持续 5 天）会导致小鼠上皮细胞增殖减少，细胞凋亡指数增加。Animal Model:ICR mice (8-week-old; CCl4-induced liver fibrosis model).
Dosage:25, 50 mg/kg
Administration:Intraperitoneal injection; twice per week for 4 weeks
Result:Markedly attenuated collagen deposition.
Animal Model:Mice with surgically induced endometriosis.
Dosage:25, 50 mg/kg
Administration:Intraperitoneal injection; single daily for 5 days
Result:Reduced the volume of observed lesions in a dose-dependent manner.Inhibited the expression of IL-6 and MCP-1.Decreased the proliferation rate of endometriotic cells and increased the percentage of apoptotic epithelial cells in the lesions.
体外研究：
ENMD-1068（10 mM；24 小时）阻断原代小鼠 HSC 中的 TGF-β1/Smad 信号传导（TGF-β1/Smad 信号通路在 HSC 激活和胶原蛋白生成中发挥着至关重要的作用）。ENMD-1068 (10 mM) 抑制 HSC 中胰蛋白酶或 SLIGRL-NH2 刺激的钙释放。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备